267 related articles for article (PubMed ID: 31848900)
1. A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
Grant TS; Burns D; Kiff C; Lee D
Pharmacoeconomics; 2020 Apr; 38(4):385-395. PubMed ID: 31848900
[TBL] [Abstract][Full Text] [Related]
2. Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review.
Sussman M; Crivera C; Benner J; Adair N
Adv Ther; 2021 Aug; 38(8):4178-4194. PubMed ID: 34251651
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
[TBL] [Abstract][Full Text] [Related]
4. Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models.
Bansal A; Sullivan SD; Lin VW; Purdum AG; Navale L; Cheng P; Ramsey SD
Med Decis Making; 2019 Apr; 39(3):294-298. PubMed ID: 30819038
[TBL] [Abstract][Full Text] [Related]
5. Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
Vadgama S; Mann J; Bashir Z; Spooner C; Collins GP; Bullement A
Value Health; 2022 Jun; 25(6):1010-1017. PubMed ID: 35667774
[TBL] [Abstract][Full Text] [Related]
6. Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.
Bullement A; Latimer NR; Bell Gorrod H
Value Health; 2019 Mar; 22(3):276-283. PubMed ID: 30832965
[TBL] [Abstract][Full Text] [Related]
7. A new cure model that corrects for increased risk of non-cancer death: analysis of reliability and robustness, and application to real-life data.
Botta L; Goungounga J; Capocaccia R; Romain G; Colonna M; Gatta G; Boussari O; Jooste V
BMC Med Res Methodol; 2023 Mar; 23(1):70. PubMed ID: 36966273
[TBL] [Abstract][Full Text] [Related]
8. Cure fraction estimation from the mixture cure models for grouped survival data.
Yu B; Tiwari RC; Cronin KA; Feuer EJ
Stat Med; 2004 Jun; 23(11):1733-47. PubMed ID: 15160405
[TBL] [Abstract][Full Text] [Related]
9. Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case Study.
Johal S; Brannman L; Genestier V; Cawston H
Clinicoecon Outcomes Res; 2024; 16():97-109. PubMed ID: 38433888
[TBL] [Abstract][Full Text] [Related]
10. Methodology to predict long-term cancer survival from short-term data using Tobacco Cancer Risk and Absolute Cancer Cure models.
Mould RF; Lederman M; Tai P; Wong JK
Phys Med Biol; 2002 Nov; 47(22):3893-924. PubMed ID: 12476973
[TBL] [Abstract][Full Text] [Related]
11. The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study.
Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
Value Health; 2021 Nov; 24(11):1634-1642. PubMed ID: 34711364
[TBL] [Abstract][Full Text] [Related]
12. Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer.
Stedman MR; Feuer EJ; Mariotto AB
J Natl Cancer Inst Monogr; 2014 Nov; 2014(49):244-54. PubMed ID: 25417238
[TBL] [Abstract][Full Text] [Related]
13. Impact of the 1990 Hong Kong legislation for restriction on sulfur content in fuel.
Wong CM; Rabl A; Thach TQ; Chau YK; Chan KP; Cowling BJ; Lai HK; Lam TH; McGhee SM; Anderson HR; Hedley AJ
Res Rep Health Eff Inst; 2012 Aug; (170):5-91. PubMed ID: 23316618
[TBL] [Abstract][Full Text] [Related]
14. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
[TBL] [Abstract][Full Text] [Related]
15. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Netw Open; 2019 Feb; 2(2):e190035. PubMed ID: 30794298
[TBL] [Abstract][Full Text] [Related]
16. Projecting overall survival in health-economic models: uncertainty and maturity of data.
Roze S; Bertrand N; Eberst L; Borget I
Curr Med Res Opin; 2023 Mar; 39(3):367-374. PubMed ID: 36628431
[TBL] [Abstract][Full Text] [Related]
17. Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.
Beca JM; Chan KKW; Naimark DMJ; Pechlivanoglou P
BMC Med Res Methodol; 2021 Dec; 21(1):282. PubMed ID: 34922454
[TBL] [Abstract][Full Text] [Related]
18. Utilization of a Mixture Cure Rate Model based on the Generalized Modified Weibull Distribution for the Analysis of Leukemia Patients.
Omer ME; Abu Bakar M; Adam M; Mustafa M
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1045-1053. PubMed ID: 33906295
[TBL] [Abstract][Full Text] [Related]
19. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
Ouwens MJNM; Mukhopadhyay P; Zhang Y; Huang M; Latimer N; Briggs A
Pharmacoeconomics; 2019 Sep; 37(9):1129-1138. PubMed ID: 31102143
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
